Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension

Cardiovascular Research

Volumn 97, Issue 4, 2013, Pages 696-704

  Nguyen, Hoanglan ^a   Chiasson, Valorie L ^a   Chatterjee, Piyali ^a   Kopriva, Shelley E ^a   Young, Kristina J ^a   Mitchell, Brett M ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

Endothelial dysfunction; Hypertension; Interleukin 17; Nitric oxide synthase

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; INTERLEUKIN 17; NEUTRALIZING ANTIBODY; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; THREONINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; VASODILATATION;

AMIDES; ANIMALS; ENDOTHELIAL CELLS; HYPERTENSION; INTERLEUKIN-17; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PYRIDINES; RATS; RHO-ASSOCIATED KINASES;

EID: 84874752603     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs422     Document Type: Article

References (58)

1. Gaffen SL. An overview of IL-17 function and signaling. Cytokine 2008;43: 402- 407.
2. Gaffen SL, Kramer JM, Yu JJ, Shen F. The IL-17 cytokine family. Vitam Horm 2006;74: 255-282.
3. Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010;129:311-321.
4. Chabaud M, Fossiez F, Taupin JL, Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998;161:409-414.
5. Hata K, Andoh A, Shimada M, Fujino S, Bamba S, Araki Y, et al. IL-17 stimulates inflammatory responses via NF-kappaB and MAP kinase pathways in human colonic myofibroblasts. Am J Physiol Gastrointest Liver Physiol 2002;282:G1035-G1044.
6. Noronha AM. New insights into the role of IL-17 in inflammatory bowel disease. Inflamm Bowel Dis 2010;16:2180-2181.
7. Liang J, Zheng Z, Wang M, Han L, Peng J, Liu Z, et al. Myeloperoxidase (MPO) and interleukin-17 (IL-17) plasma levels are increased in patients with acute coronary syndromes. J Int Med Res 2009;37:862-866.
8. Csiszar A, Ungvari Z. Synergistic effects of vascular IL-17 and TNFalpha may promote coronary artery disease. Med Hypotheses 2004;63:696-698.
9. Jafarzadeh A, Esmaeeli-Nadimi A, Nough H, Nemati M, Rezayati MT. Serum levels of interleukin (IL)-13, IL-17 and IL-18 in patients with ischemic heart disease. Anadolu Kardiyol Derg 2009;9:75-83.
10. Madhur MS, Lob HE, McCann LA, Iwakura Y, Blinder Y, Guzik TJ, et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 2010;55:500-507.
11. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007;204:2449-2460.
12. Harrison DG, Guzik TJ, Goronzy J, Weyand C. Is hypertension an immunologic disease? Curr Cardiol Rep 2008;10:464-469.
13. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, et al. Inflammation, immunity, and hypertension. Hypertension 2011;57:132-140.
14. Marvar PJ, Thabet SR, Guzik TJ, Lob HE, McCann LA, Weyand C, et al. Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension. Circ Res 2010;107:263-270.
15. Santner-Nanan B, Peek MJ, Khanam R, Richarts L, Zhu E, Fazekas de St Groth B, et al. Systemic increase in the ratio between FoxP3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia. J Immunol 2009;183:7023-7030.
16. Wong CK, Ho CY, Li EK, Lam CW. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000;9:589-593.
17. Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008;127:385-393.
18. Zhang Z, Kyttaris VC, Tsokos GC. The role of IL-23/IL-17 axis in lupus nephritis. J Immunol 2009;183:3160-3169.
19. Antonysamy MA, Fanslow WC, Fu F, LiW, Qian S, Troutt AB, et al. Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol 1999;162:577-584.
20. Booth AJ, Bishop DK. TGF-beta, IL-6, IL-17 and CTGF direct multiple pathologies of chronic cardiac allograft rejection. Immunotherapy 2010;2:511-520.
21. Itoh S, Nakae S, Axtell RC, Velotta JB, Kimura N, Kajiwara N, et al. IL-17 contributes to the development of chronic rejection in a murine heart transplant model. J Clin Immunol 2010;30:235-240.
22. Chen L, Ahmed E,Wang T,Wang Y, Ochando J, Chong AS, et al. TLR signals promote IL-6/IL-17-dependent transplant rejection. J Immunol 2009;182:6217-6225.
23. Schiffrin EL. T lymphocytes: a role in hypertension? Curr Opin Nephrol Hypertens 2010; 19:181-186.
24. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther 2001;299: 818-824.
25. Mount PF, Kemp BE, Power DA. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol 2007;42:271-279.
26. Fleming I, Fisslthaler B, Dimmeler S, Kemp BE, Busse R. Phosphorylation of THR(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res 2001;88:E68-E75.
27. Lin MI, Fulton D, Babbitt R, Fleming I, Busse R, Pritchard KA Jr, et al. Phosphorylation of threonine 497 in endothelial nitric-oxide synthase coordinates the coupling of Larginine metabolism to efficient nitric oxide production. J Biol Chem 2003;278: 44719-44726.
28. Long C, Cook LG, Hamilton SL, Wu GY, Mitchell BM. FK506 binding protein 12/12.6 depletion increases endothelial nitric oxide synthase threonine 495 phosphorylation and blood pressure. Hypertension 2007;49:569-576.
29. Long C, Cook LG, Wu GY, Mitchell BM. Removal of FKBP12/12.6 from endothelial ryanodine receptors leads to an intracellular calcium leak and endothelial dysfunction. Arterioscler Thromb Vasc Biol 2007;27:1580-1586.
30. Cook LG, Chiasson VL, Long C, Wu GY, Mitchell BM. Tacrolimus reduces nitric oxide synthase function by binding to FKBP rather than by its calcineurin effect. Kidney Int 2009;75:719-726.
31. Gentile MT, Vecchione C, Maffei A, Aretini A, Marino G, Poulet R, et al. Mechanisms of soluble beta-amyloid impairment of endothelial function. J Biol Chem 2004;279: 48135-48142.
32. Jiang X, Yang F, Tan H, Liao D, Bryan RM Jr, Randhawa JK, et al. Hyperhomocystinemia impairs endothelial function and eNOS activity via PKC activation. Arterioscler Thromb Vasc Biol 2005;25:2515-2521.
33. Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (c-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens 2005;19:149-154.
34. Davis JR, Giardina JB, Green GM, Alexander BT, Granger JP, Khalil RA. Reduced endothelial NO-cGMP vascular relaxation pathway during TNF-alpha-induced hypertension in pregnant rats. Am J Physiol Regul Integr Comp Physiol 2002;282:R390-R399.
35. Gu JW, Tian N, Shparago M, Tan W, Bailey AP, Manning RD Jr. Renal NF-kappaB activation and TNF-alpha upregulation correlate with salt-sensitive hypertension in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol 2006;291:R1817-R1824.
36. Orshal JM, Khalil RA. Reduced endothelial NO-cGMP-mediated vascular relaxation and hypertension in IL-6-infused pregnant rats. Hypertension 2004;43:434-444.
37. Lin RC, Morris BJ. Association analysis of polymorphisms at the interleukin-1 locus in essential hypertension. Am J Med Genet 2002;107:311-316.
38. Jovcic G, Bugarski D, Petakov M, Krstic A, Vlaski M, Stojanovic N, et al. In vivo effects of interleukin-17 on haematopoietic cells and cytokine release in normal mice. Cell Prolif 2004;37:401-412.
39. Jovcic G, Bugarski D, Krstic A, Vlaski M, Petakov M, Mojsilovic S, et al. The effect of interleukin-17 on hematopoietic cells and cytokine release in mouse spleen. Physiol Res 2007;56:331-339.
40. Wang S, Liang B, Viollet B, Zou MH. Inhibition of the AMP-activated protein kinase-alpha2 accentuates agonist-induced vascular smooth muscle contraction and high blood pressure in mice. Hypertension 2011;57:1010-1017.
41. Chiasson VL, Talreja D, Young KJ, Chatterjee P, Banes-Berceli AK, Mitchell BM. FK506 binding protein 12 deficiency in endothelial and hematopoietic cells decreases regulatory T cells and causes hypertension. Hypertension 2011;57:1167-1175.
42. Roussel L, Houle F, Chan C, Yao Y, Berube J, Olivenstein R, et al. IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation. J Immunol 2010;184:4531-4537.
43. Starnes T, Robertson MJ, Sledge G, Kelich S, Nakshatri H, Broxmeyer HE, et al. Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. J Immunol 2001;167:4137-4140.
44. Kim JS, Kim JG, Moon MY, Jeon CY, Won HY, Kim HJ, et al. Transforming growth factor-beta1 regulates macrophage migration via RhoA. Blood 2006;108:1821-1829.
45. Turcotte S, Desrosiers RR, Beliveau R. HIF-1alpha mRNA and protein upregulation involves Rho GTPase expression during hypoxia in renal cell carcinoma. J Cell Sci 2003;116:2247-2260.
46. Marshall AK, Barrett OP, Cullingford TE, Shanmugasundram A, Sugden PH, Clerk A. ERK1/2 signaling dominates over RhoA signaling in regulating early changes in RNA expression induced by endothelin-1 in neonatal rat cardiomyocytes. PLoS One 2010; 5:e10027.
47. Shah DI, Singh M. Effect of fasudil on macrovascular disorder-induced endothelial dysfunction. Can J Physiol Pharmacol 2006;84:835-845.
48. Bussemaker E, Pistrosch F, Forster S, Herbrig K, Gross P, Passauer J, et al. Rho kinase contributes to basal vascular tone in humans: role of endothelium-derived nitric oxide. Am J Physiol Heart Circ Physiol 2007;293:H541-H547.
49. Versteilen AM, Korstjens IJ, Musters RJ, Groeneveld AB, Sipkema P. Rho kinase regulates renal blood flow by modulating eNOS activity in ischemia-reperfusion of the rat kidney. Am J Physiol Renal Physiol 2006;291:F606-F611.
50. Taflin C, Favier B, Baudhuin J, Savenay A, Hemon P, Bensussan A, et al. Human endothelial cells generate Th17 and regulatory T cells under inflammatory conditions. Proc Natl Acad Sci USA 2011;108:2891-2896.
51. Chen H, Wang W, Xie H, Xu X, Wu J, Jiang Z, et al. A pathogenic role of IL-17 at the early stage of corneal allograft rejection. Transpl Immunol 2009;21:155-161.
52. Dong G, Ye R, Shi W, Liu S, Wang T, Yang X, et al. IL-17 induces autoantibody overproduction and peripheral blood mononuclear cell overexpression of IL-6 in lupus nephritis patients. Chin Med J (Engl) 2003;116:543-548.
53. Crispin JC, Tsokos GC. IL-17 in systemic lupus erythematosus. J Biomed Biotechnol 2010;2010:943254.
54. Doe C, Bentley R, Behm DJ, Lafferty R, Stavenger R, Jung D, et al. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther 2007;320:89-98.
55. Myung SC, Han JH, Song KK, Kang GH, Lee SY, Kim TH, et al. The effects of interleukin-6 on the contraction and relaxation responses of the cavernous smooth muscle from rats. Eur J Pharmacol 2008;589:228-232.
56. Schrader LI, Kinzenbaw DA, Johnson AW, Faraci FM, Didion SP. IL-6 deficiency protects against angiotensin II induced endothelial dysfunction and hypertrophy. Arterioscler Thromb Vasc Biol 2007;27:2576-2581.
57. Huang H, Kim HJ, Chang EJ, Lee ZH, Hwang SJ, Kim HM, et al. IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: Implications for bone remodeling. Cell Death Differ 2009;16:1332-1343.
58. Huppert J, Closhen D, Croxford A, White R, Kulig P, Pietrowski E, et al. Cellular mechanisms of IL-17-induced blood-brain barrier disruption. FASEB J 2010;24: 1023-1034.